Reining In “March In”: NIH Rejects Xtandi Petition
This article was originally published in RPM Report
Executive Summary
The National Institutes of Health is rejecting calls to exercise “march in” rights on patents for a cancer drug, declaring its view that the authority is narrowly focused on shortages – not pricing.
You may also be interested in...
After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?
Market availability of Xtandi, not its cost, is the issue, NIH says in denying petition for government to invoke march-in rights to patents on the prostate cancer drug. But Biden administration makes two other same-day moves that could leave march-in advocates with some hope.
Xtandi March-In Fight Extended to Paxlovid, Insulin, HIV, Asthma And Hepatitis C Drugs
In drug pricing move, Public Citizen and others petition HHS Secretary Becerra to use government authorities to get generic versions of six drugs on the market before patent expiration.
Xtandi March-In Fight Extended to Paxlovid, Insulin, HIV, Asthma And Hepatitis C Drugs
In drug pricing move, Public Citizen and others petition HHS Secretary Becerra to use government authorities to get generic versions of six drugs on the market before patent expiration.